Belkyra is the first-in-class treatment, clinically proven to destroy fat cells under chin to improve submental contour2-5.

With the patent formulation of deoxycholic acid (DCA), which is bioequivalent to the naturally occurring molecule, Belkyra specifically target to destroy undesired fat, resulting in a noticeable reduction in fullness under the chin.

Belkyra Technology

The course of treatment uses the patented ingredient DCA deoxycholic acid to decompose the fat cells at fixed points

DCA is a synthetic form of a natural substance created by your body that destroys fat7

Directly reaches the fat layer, permanently destroy fat cells2

Approved by FDA and EMA, safe and reliable1

Belkyra Principle

Deoxycholic acid (DCA) is a synthetic form of a natural substance created by your body that absorbs and destroys fat. DCA works by destroying the outer layer of a fat cell causing it to burst, thus, destroying fat cells where it is injected into the body.

Once destroyed, those cells are more easily excreted from the body5.

Photo courtesy of Belkyra.

Belkyra Effect

Clinically proven Belkyra to be effective and safe!

    • Permanently destroy fat cells3
    • Non-surgical procedure
    • Long term safety study data up to 5 years9

Suggested course of treatment:
Average 2-4 treatment sessions. Maximum of 6 treatments maybe administered. Each session taking about 30 minutes.

Belkyra Treatment Before & After

Photo courtesy of Belkyra


Since everyone’s chin profile is different, the number of treatments varies from one to another. According to clinic studies, most users undergo 2 – 4 treatment sessions to achieve expected results, and a maximum of 6 treatments maybe administered6*.

Belkyra causes the destruction of fat cells under chin. Once destroyed, those cells cannot store or accumulate fat. After reaching your desired aesthetic, further treatment is not expected8*.

After treatment, you may experience swelling, pain, or numbness under your chin. Most condition will resolve gradually within 30 days10*.

*The effect varies from person to person

  1. U.S. Food and Drug Administration, Department of Health & Human Services. Kyrbella™ deoxycholic acid
  2. Ascher B, et al. J Eur Acad Dermatol Venereol 2014 Dec;28(12):1707-15;
  3. Humphrey S, et al. J Am Acad Dermatol 2016;75(4):788-797;
  4. Jones DH, et al. Dermatol Surg 2016;42(1):38-49;
  5. Rzany B, et al. Br J Dermatol. 2014;170(2):445-453;
  6. Belkyra® Prescribing Information. March 2021;
  7. Jones DH, et al. Dermatol Surg 2016;42(1):38-49;
  8. Rzany B, et al. Br J Dermatol. 2014;170:445–53;
  9. Bhatia AC, et al. Poster presented at The Maui Derm for Dermatologists Conference. 20-24 March 2017;
  10. Teller CF et al. Plast Reconstr Surg Glob Open. 2021 Jul 12;9(7):e3668